Saleh Ahmed Mohamed, Hassan Essam Ali, Gomaa Ahmed Ali, El Baz Tamer Mahmoud, El-Abgeegy Mohamed, Seleem Mohamed Ismail, Abo-Amer Yousry Esam-Eldin, Elsergany Heba Fadl, Mahmoud Eman Ibrahim El-Desoki, Abd-Elsalam Sherief
Tropical Medicine Department, Fayoum University, Al Fayyum, Egypt.
Endemic Medicine Department, Cairo University, Giza, Egypt.
Infect Drug Resist. 2019 Jul 24;12:2277-2282. doi: 10.2147/IDR.S208954. eCollection 2019.
Liver transplantation (LT) has emerged as an established therapeutic option for patients with chronic liver disease. Patients with end-stage liver disease are at high risk of infection with multidrug-resistant organisms, which may affect the outcome of LT. The aim of this study was to evaluate the impact of pre-transplant infection on the outcome of living-donor LT.
Prospective follow-up was done for 50 patients with chronic liver disease who had had LT performed from September 2013 to December 2017. We divided patients into group 1 (patients who had had infection within 3 months before transplantation with adequate treatment [n=20]), and group 2 (patients without infection [n=30]). Both groups were followed for 4 months post-operatively.
Patients with high Model for End-Stage Liver Disease scores were more susceptible to infection pre- and post-operatively, and chest infection was the most common infection pre-transplant. There were no significant statistical differences regarding hospital and ICU stay and post-operative course between the groups, but the mortality rate was higher in group 1 (40%) than in group 2 (23.3%), and the causes of mortality in the group 1 were mainly due to medical causes (infections and sepsis, 75%) versus 28.6% in group 2.
Liver-cell failure and concomitant infection 3 months before LT with adequate treatment had no significant statistical differences regarding hospital, ICU stay, or medical complications, but post-operative infection and mortality rate were more frequent in group 1 and the causes of mortality were mainly medical.
肝移植(LT)已成为慢性肝病患者公认的治疗选择。终末期肝病患者感染多重耐药菌的风险很高,这可能会影响肝移植的结果。本研究的目的是评估移植前感染对活体肝移植结果的影响。
对2013年9月至2017年12月期间接受肝移植的50例慢性肝病患者进行前瞻性随访。我们将患者分为第1组(移植前3个月内发生感染且治疗充分的患者[n = 20])和第2组(未发生感染的患者[n = 30])。两组患者均在术后随访4个月。
终末期肝病模型评分高的患者在术前和术后更容易感染,移植前最常见的感染是肺部感染。两组患者在住院时间、重症监护病房(ICU)停留时间和术后病程方面无显著统计学差异,但第1组的死亡率(40%)高于第2组(23.3%),第1组的死亡原因主要是医疗原因(感染和脓毒症,75%),而第2组为28.6%。
肝移植前3个月出现肝细胞衰竭并伴有感染且治疗充分,在住院时间、ICU停留时间或医疗并发症方面无显著统计学差异,但第1组术后感染和死亡率更高,且死亡原因主要是医疗原因。